Breaking News, Financial News

Financial Report: Charles River Laboratories

Safety Assessment and EMD businesses are primary drivers of growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories   2Q Revenues: $339.6 million (flat) 2Q Earnings: $49.2 million (+37%) YTD Revenues: $660.0 million (+3%) YTD Earnings: $80.9 million (+19%) Comments: Research Models and Services (RMS) revenues were $120.0 million in the quarter, down 10%, impacted by foreign exchange. Higher sales of research models were offset by lower revenue for the Genetically Engineered Models and Services (GEMS) business. Discovery and Safety Assessment (DSA) revenues were $153.4 ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters